Kelly K. Filipski, Ph.D., M.P.H.
- Ph.D. - Integrated Program in Biomedical Sciences, Molecular Therapeutics and Cell Signaling, The University of Tennessee Health Science Center
- M.P.H., Johns Hopkins University, Bloomberg School of Public Health
- B.S. - Biology and Psychology, Heidelberg University
- Cancer survivorship
- Treatment-related adverse events
- Adolescent and young adult cancer
Dr. Kelly Filipski is a Program Director in the Clinical and Translational Epidemiology Branch (CTEB) of the Epidemiology and Genomics Research Program (EGRP) in NCI’s Division of Cancer Control and Population Sciences (DCCPS). Her focus is on epidemiologic studies evaluating prognostic and predictive genomic markers of treatment response and/or treatment related adverse events.
Dr. Filipski is currently overseeing a funding opportunity focusing on the clinical characterization of cancer treatment-related adverse events, and she has been involved with the NCI Provocative Questions Requests for Applications (RFAs).
Dr. Filipski’s personal research interests include clinical phenotyping of cancer treatment-related adverse events and the utilization and adverse event rates of molecularly targeted therapies and immunotherapies. She is also interested in cancer treatment during pregnancy, fertility and pregnancy outcomes in young adult cancer patients and survivors.
Prior to joining CTEB, Dr. Filipski was an NCI Cancer Prevention Fellow with a focus on genomics in drug development and clinical pharmacology.